STOCK TITAN
  1. Home
  2. News
  3. FDMT

4D Molecular Therapeutics, Inc. - FDMT STOCK NEWS

Welcome to our dedicated page for 4D Molecular Therapeutics news (Ticker: FDMT), a resource for investors and traders seeking the latest updates and insights on 4D Molecular Therapeutics stock.

4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) is a clinical-stage gene therapy company dedicated to developing transformative medicines for serious, unmet medical conditions. Utilizing its proprietary Therapeutic Vector Evolution platform, the company designs novel adeno-associated virus (AAV) vectors to treat genetic diseases.

Core Business: 4DMT focuses on three primary therapeutic areas: Ophthalmology, Cardiology, and Pulmonology. In ophthalmology, intravitreal vectors are employed for treatments like 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Cardiology projects include 4D-310 for Fabry disease cardiomyopathy, while pulmonology efforts are highlighted by 4D-710 for cystic fibrosis.

Recent Achievements: The company has shown promising interim safety and efficacy data for 4D-310 in treating Fabry disease cardiomyopathy, with significant improvements in cardiac function, exercise capacity, and quality of life. For 4D-150, positive interim results from the PRISM clinical trial indicate its potential as a best-in-class treatment for wet AMD, leading to the initiation of a Phase 3 clinical trial in 2025.

Partnerships and Financial Condition: 4DMT has established strategic partnerships and recently secured substantial financing, bolstering its financial health. The company reported $589 million in cash equivalents by Q1 2024, sufficient to fund operations into the first half of 2027.

Innovative Pipeline: 4DMT’s product candidates, currently in clinical and preclinical stages, include 4D-175 for geographic atrophy, 4D-725 for A1AT deficiency, and additional CNS programs through gene editing partnerships. The company’s advanced manufacturing processes support the potential commercialization of these therapies.

Learn more at www.4DMT.com and follow on LinkedIn.

News

4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

Rhea-AI Summary
4D Molecular Therapeutics announces regulatory interactions and development path for 4D-710, an aerosolized genetic medicine for cystic fibrosis lung disease. Positive clinical data, technology transfer, and pivotal trial plans revealed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.18%
Tags
none
-
News

4DMT to Participate in Upcoming Investor Conferences

Rhea-AI Summary
4D Molecular Therapeutics (FDMT) to participate in investor conferences in March 2024, presenting at Leerink Partners Global Biopharma Conference and Barclays Annual Global Healthcare Conference. Management team to engage in fireside chats and one-on-one meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
conferences
-
News

4DMT Reports Full Year 2023 Financial Results and Operational Highlights

Rhea-AI Summary
4D Molecular Therapeutics reported positive interim data from Phase 2 PRISM study, advancing into Phase 3 development. The company showcased clinical progress in multiple therapeutic areas, strong financial results, and strategic agreements with Astellas Pharma and Arbor Biotechnologies. 4DMT's cash position of $299 million extends operational runway into 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.82%
Tags
earnings
News

4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024

Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) announces positive interim safety and efficacy data on 4D-310 for Fabry disease cardiomyopathy, showcasing improvements in cardiac function, exercise capacity, and quality of life. The therapy demonstrated efficient delivery, transgene expression, and clearance of Gb3 substrate in cardiomyocytes, with no new adverse events reported.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
clinical trial
-
News

4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

Rhea-AI Summary
4D Molecular Therapeutics, Inc. (FDMT) announced the pricing of an upsized underwritten public offering of its common stock, with a 30-day option to purchase additional shares. The gross proceeds from the offering are expected to be approximately $300 million. The offering is expected to close on February 9, 2024, and is managed by Goldman Sachs & Co. LLC, BofA Securities, Jefferies, and Barclays. The registration statement was automatically effective upon filing on February 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.97%
Tags
offering
-
News

4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock

Rhea-AI Summary
4D Molecular Therapeutics, Inc. (FDMT) has announced a public offering of $250.0 million of its common stock with an option for underwriters to purchase an additional $37.5 million. The offering is subject to market conditions, and the company has filed a registration statement with the SEC. The joint book-running managers for the offering are Goldman Sachs & Co. LLC, BofA Securities, Jefferies, and Barclays.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.85%
Tags
offering
News

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD

Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) announced positive interim data from the Phase 2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration (wet AMD) patients with severe disease activity and a high treatment burden. The study showed that 4D-150 was well tolerated, resulting in an 89% reduction in the annualized anti-VEGF injection rate. The positive interim results enable rapid advancement towards pivotal development, with Phase 3 clinical trial initiation expected in Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
84.62%
Tags
clinical trial
-
News

4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden

Rhea-AI Summary
4D Molecular Therapeutics (FDMT) announces a live webcast to discuss interim data from the intravitreal 4D-150 Phase 2 PRISM clinical trial in wet AMD patients with severe disease activity and high treatment burden. The company will also provide a program update on Monday, February 5, 2024. The webcast will be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial. The presentation of the interim results will also be available at the Angiogenesis, Exudation, and Degeneration 2024 Conference on Saturday, February 3, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
conferences clinical trial
-
News

4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease

Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) announced that the U.S. FDA granted Rare Pediatric Disease Designation for aerosolized 4D-710, a treatment for cystic fibrosis lung disease. Promising clinical trial results showed significant CFTR expression levels and improved quality of life for patients. The company is also planning an interim data update and pivotal trial planning update for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
none
News

TurnCare, Inc. Announces John F. Milligan, PhD, former CEO of Gilead Sciences, joins Board of Directors

Rhea-AI Summary
TurnCare, a leading medical technology and services company dedicated to advancing how hospitals manage high acuity patients, proudly announces the addition of John F. Milligan, Ph.D., investor, innovator, and former CEO of Gilead, to its Board of Directors. Dr. Milligan's expertise includes driving major acquisitions to create unique industry solutions and scaling Gilead to over $21 Billion in worldwide sales with a market cap of $85 Billion. He brings a unique and valuable perspective that will help TurnCare maximize the impact of its novel patient management technologies as it scales to more networks, hospitals, and patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
management

FAQ

What is the current stock price of 4D Molecular Therapeutics (FDMT)?

The current stock price of 4D Molecular Therapeutics (FDMT) is $8.095 as of November 1, 2024.

What is the market cap of 4D Molecular Therapeutics (FDMT)?

The market cap of 4D Molecular Therapeutics (FDMT) is approximately 420.7M.

What is 4D Molecular Therapeutics' core business?

4DMT focuses on developing transformative gene therapy products for ophthalmology, cardiology, and pulmonology using proprietary AAV vectors.

What recent achievements has 4D Molecular Therapeutics accomplished?

The company has shown promising interim data for 4D-310 in Fabry disease cardiomyopathy and initiated a Phase 3 clinical trial for 4D-150 in wet AMD.

What are the key products in 4DMT's pipeline?

Key products include 4D-150 for wet AMD, 4D-310 for Fabry disease, 4D-710 for cystic fibrosis, and 4D-725 for A1AT deficiency.

How is 4DMT financially positioned?

4DMT reported $589 million in cash equivalents in Q1 2024, sufficient to fund operations into the first half of 2027.

What partnerships has 4DMT established?

4DMT has strategic partnerships in gene editing and other areas to advance its diverse product pipeline.

What is the Therapeutic Vector Evolution platform?

It's 4DMT's proprietary platform that employs directed evolution to create novel AAV vectors tailored for specific therapeutic applications.

What is 4D-150 and what does it treat?

4D-150 is a gene therapy product for treating wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Where can I find more information about 4D Molecular Therapeutics?

Visit their website at www.4DMT.com and follow them on LinkedIn for updates and further details.

What are the clinical-stage products in 4DMT’s pipeline?

4DMT has five clinical-stage products: 4D-150, 4D-310, 4D-710, 4D-725, and 4D-175.

What is the significance of 4D-310's interim data for Fabry disease?

The data show significant improvements in cardiac function, exercise capacity, and quality of life, indicating strong clinical activity and safety.

Stock FDMT logo
4D Molecular Therapeutics, Inc.

Nasdaq:FDMT

FDMT Rankings

#3231 Ranked by Market Cap
N/A Ranked by Dividends

FDMT Stock Data

420.69M
51.97M
3.48%
114.88%
18.26%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
EMERYVILLE